MedTrace Logo

Inhibition of Aldosterone in Patients With Chronic Renal Disease

NCT00430924 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-02-08

No results posted yet for this study

Summary

The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine. The hypothesis is that if loss of protein is lowered, progression of renal disease with be slower than otherwise expected.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Eplerenone

Once daily administration for 8 weeks and 8 weeks control.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Lene Boesby

    lead OTHER

Principal Investigators

  • Svend Strandgaard, DMSc

  • Anne-Lise Kamper, DMSc · nonaffiliated

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430924 on ClinicalTrials.gov